FDA vouchers were created as an incentive to encourage drug companies to work on medicines for neglected diseases.
In March, when the Food and Drug Administration gave the OK to a new treatment for a parasitic disease called leishmaniasis, the Canadian company that owns the medicine got something that’s quite likely to prove even more valuable than U.S. sales of the drug will ever be.
Continue reading… “FDA vouchers encourage drug companies to focus on neglected diseases”
